<b draggable="R9NaNL"><bdo draggable="KOTLj"></bdo></b><area dropzone="E8R91"></area> Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The . gov means it’s official. Federal government websites often end in . gov or . mil. Before sharing sensitive information, make sure you’re on a federal government site VSports app下载. .

Https

The site is secure. The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely V体育官网. .

Review
. 2021 May 11;10(10):2050.
doi: 10.3390/jcm10102050.

The Role of Myeloid-Derived Suppressor Cells (MDSCs) in Graft-versus-Host Disease (GVHD)

Christos Demosthenous  1 , Ioanna Sakellari  1 , Vassiliki Douka  1 , Penelope Georgia Papayanni  1 , Achilles Anagnostopoulos  1 , Eleni Gavriilaki  1
Affiliations
Review

VSports - The Role of Myeloid-Derived Suppressor Cells (MDSCs) in Graft-versus-Host Disease (GVHD)

Christos Demosthenous (VSports最新版本) et al. J Clin Med. .

VSports在线直播 - Abstract

Background: Myeloid-derived suppressor cells (MDSCs) are implicated in the complex interplay involving graft-versus-leukemia (GVL) effects and graft-versus-host disease (GVHD) after allogeneic hematopoietic stem cell transplantation (allo-HCT) in hematologic malignancies. VSports手机版.

Methods: A review of literature through PubMed was undertaken to summarize the published evidence on the pathophysiology and clinical implications of MDSCs in allo-HCT V体育安卓版. Literature sources published in English since 1978 were searched, using the terms Natural Suppressor (NS) cells, MDSCs, GVHD, and allo-HCT. .

Results: In vivo studies demonstrated that MDSCs derived from mobilization protocols could strongly suppress allo-responses mediated by T cells and enhance T-Reg activity, thus inhibiting GVHD toxicity. However, the influence of MDSCs on the GVL effect is not fully defined. V体育ios版.

Conclusions: The induction or maintenance of MDSC suppressive function would be advantageous in suppressing inflammation associated with GVHD. Pathways involved in MDSC metabolism and the inflammasome signaling are a promising field of study to elucidate the function of MDSCs in the pathogenesis of GVHD and translate these findings to a clinical setting VSports最新版本. .

Keywords: GVHD; GVL; MDSCs; NS cells; allo-HCT V体育平台登录. .

PubMed Disclaimer

Conflict of interest statement (VSports手机版)

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Implications of MDSCs in GVHD. Myeloid-derived suppressor cells (MDSCs) are generated under inflammatory conditions. Inflammatory factors that induce MDSC recruitment and expansion include GM-CSF, G-CSF, M-CSF, and proinflammatory cytokines. Three different subsets of MDSCs have been identified according to their cellular markers; granulocytes, monocytes, and early stage MDSCs. The role of MDSC in the pathogenesis of GVHD would be beneficial through two mechanisms: (1) Immunosuppressive activity of MDSCs by regulating the secretion of various factors, among which ARG1, iNOS, and IDO; (2) Induction and expansion of T Regs. GM-CSF, granulocyte–macrophage colony-stimulating factor; G-CSF, granulocyte colony-stimulating factor; M-CSF, macrophage colony-stimulating factor; HSC, hematopoietic stem cells; HCT, hematopoietic cell transplantation; IFA, incomplete Freund’s adjuvant; RAPA, rapamycin; Gal-9, galectin-9; I-Arg, L-arginine; IFN-γ, interferon gamma; NO, nitric oxide; NLRP3, NLR pyrin family domain 3; AIM2, absent in melanoma 2; aGVHD, acute Graft-versus-Host Disease; ARG1, arginase 1; iNOS, inducible nitric oxide synthase; IDO, indoleamine 2,3-dioxygenase; ROS, reactive oxygen species; TGFβ, transforming growth factor beta; IL-6, IL-10, interleukin-6, interleukin-10.
See this image and copyright information in PMC

References

    1. Socie G., Ritz J. Current issues in chronic graft-versus-host disease. Blood. 2014;124:374–384. doi: 10.1182/blood-2014-01-514752. - DOI - PMC - PubMed
    1. Wingard J.R., Majhail N.S., Brazauskas R., Wang Z., Sobocinski K.A., Jacobsohn D., Sorror M.L., Horowitz M.M., Bolwell B., Rizzo J.D., et al. Long-term survival and late deaths after allogeneic hematopoietic cell transplantation. J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. 2011;29:2230–2239. doi: 10.1200/JCO.2010.33.7212. - DOI - PMC - PubMed
    1. Dignan F.L., Clark A., Amrolia P., Cornish J., Jackson G., Mahendra P., Scarisbrick J.J., Taylor P.C., Hadzic N., Shaw B.E., et al. Diagnosis and management of acute graft-versus-host disease. Br. J. Haematol. 2012;158:30–45. doi: 10.1111/j.1365-2141.2012.09129.x. - DOI - PubMed
    1. Perez L., Anasetti C., Pidala J. Have we improved in preventing and treating acute graft-versus-host disease? Curr. Opin. Hematol. 2011;18:408–413. doi: 10.1097/MOH.0b013e32834b6196. - DOI (V体育安卓版) - PMC - PubMed
    1. Jagasia M., Perales M.A., Schroeder M.A., Ali H., Shah N.N., Chen Y.B., Fazal S., Dawkins F.W., Arbushites M.C., Tian C., et al. Ruxolitinib for the treatment of steroid-refractory acute GVHD (REACH1): A multicenter, open-label phase 2 trial. Blood. 2020;135:1739–1749. doi: 10.1182/blood.2020004823. - V体育官网 - DOI - PMC - PubMed